Genentech, a member of the Roche (RHHBY), and AbbVie (ABBV) announced today the outcome from the Phase III VERONA study investigating Venclexta plusazacitidine for patients with previously untreated higher-risk myelodysplastic syndromes. The study did not meet the primary endpoint of overall survival at the final analysis. The safety profile of the Venclexta combination was consistent with the known risk of the individual study medicines and no unexpected safety signals were observed, the companies added. The results of the VERONA study have no impact on the approved indications for Venclexta or any ongoing studies, they added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Prothena partner Roche advances prasinezumab into Phase 3
- Genentech to proceed with Phase III development of prasinezumab
- Senators to propose ban on drug ads to consumers, WSJ reports
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
- Roche CEO says Trump’s drug pricing order threatens investment, WSJ reports
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue